Pregled bibliografske jedinice broj: 111759
Radioiodine Therapy of Graves' Hyperthyroidism: One Year Follow-up Study
Radioiodine Therapy of Graves' Hyperthyroidism: One Year Follow-up Study // Book of Abstracts of the Fourth International Congress of the Croatian Society of Nuclear Medicine, May 12-15, 2002, Opatija - Croatia / Prof. dr. Damir Dodig (ur.).
Zagreb: Medicinska naklada, 2002. (predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 111759 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Radioiodine Therapy of Graves' Hyperthyroidism: One Year Follow-up Study
Autori
Punda, Marija ; Novosel, Sunčica Andrea ; Labar, Željka ; Kusić, Zvonko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Book of Abstracts of the Fourth International Congress of the Croatian Society of Nuclear Medicine, May 12-15, 2002, Opatija - Croatia
/ Prof. dr. Damir Dodig - Zagreb : Medicinska naklada, 2002
Skup
Fourth International Congress of the Croatian Society of Nuclear Medicine
Mjesto i datum
Opatija, Hrvatska, 12.05.2002. - 15.05.2002
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
radioiodine; therapy; hyperthyroidism; thyroid; outcome
Sažetak
The aim of the study was to evaluate clinical outcome in patients (pts) treated using a 131-iodine (131-I) with doses adjusted for each pt according to thyroid gland weight and 131-I uptake. Patients and methods: In the study were included 83 pts with Graves' hyperthyroidism, 9 males and 74 females (ages ranged from 28 to 73, mean 49, 8). They were previously treated with antithyroid drugs. Patients were followed-up at least 12 months (median 20 months). Hormonal thyroid status was reviewed at 3, 6 and 12 months after 131-I treatment. Results: In presented study 60 (72%) pts out of 83 required a single therapeutic dose, 17 (21%) received one additional dose, and 6 (7%) were treated with three doses of 131-I. Three months after a treatment 50 (60%) pts responded to the iodine therapy: 28 (33%) pts were euthyroid and 22 (27%) pts were hypothyroid. Six months after the first 131-I treatment, successful outcome was documented in 53 (64%) pts and one year after in 61 (74%) pts: 39 (47%) were hypothyroid and 22 (27%) were euthyroid Finally, such cure rate was achieved with a single dose in 52 (85%) pts and 9 pts needed additional doses. One year after the initial treatment there were still 22 (26%) hyperthyroid pts. The second 131-I treatment was performed after a median of 9 months (range 4-26) and the third after a median of 14 months (range 6-25). Conclusion: Patients with hyperthyroidism can be treated with high efficiency, using doses of 131-I adjusted to thyroid gland weight and 131-I uptake, although at the costs of thyroid failure.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
